MiMedx Group Inc
$ 5.12
0.59%
13 Feb - close price
- Market Cap 753,840,000 USD
- Current Price $ 5.12
- High / Low $ 5.24 / 5.08
- Stock P/E 18.85
- Book Value 1.61
- EPS 0.27
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.19 %
- 52 Week High 8.50
- 52 Week Low 4.89
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Analyst Target Price
$10.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-29 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-04-30 | 2024-02-28 | 2023-10-30 | 2023-08-01 | 2023-05-02 | 2023-02-28 |
| Reported EPS | 0.15 | 0.1 | 0.05 | 0.07 | 0.05 | 0.12 | 0.07 | 0.32 | 0.06 | -0.0046 | -0.06 | -0.02 |
| Estimated EPS | 0.06 | 0.054 | 0.055 | 0.075 | 0.04 | 0.08 | 0.05 | 0.07 | 0.05 | -0.02 | -0.09 | -0.04 |
| Surprise | 0.09 | 0.046 | -0.005 | -0.005 | 0.01 | 0.04 | 0.02 | 0.25 | 0.01 | 0.0154 | 0.03 | 0.02 |
| Surprise Percentage | 150% | 85.1852% | -9.0909% | -6.6667% | 25% | 50% | 40% | 357.1429% | 20% | 77% | 33.3333% | 50% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXG
2026-02-06 14:58:56
Northland Securities has revised its Q1 2026 EPS estimate for MiMedx Group (NASDAQ:MDXG) down to $0.00 from $0.02, while forecasting Q3 and Q4 EPS of $0.04 and $0.05, respectively. The company currently holds a "Moderate Buy" consensus rating with an average target price of $10.67, significantly above its current trading price of $5.03. MiMedx Group, a biopharmaceutical company specializing in regenerative biomaterial products, is characterized by a market cap of approximately $745 million and high institutional ownership.
2026-02-06 11:29:08
MiMedx Group, Inc. has entered into an exclusive distribution partnership with Summit Products Group for three FDA 510(k) cleared surgical wound care products: Hydrelix, NovaForm, and G4Derm Plus. This strategic move aims to expand MiMedx's commercial reach and reduce reliance on single product segments, especially in response to new U.S. healthcare regulations from CMS effective January 1. The company's fourth-quarter and full-year 2025 financial results, due February 25, are anticipated to reveal the impact of this new strategy.
2026-02-05 04:29:04
MIMEDX Group, Inc. has announced an exclusive distribution agreement with Summit Products Group for three new 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. These products, which include collagen matrix, bioglass and collagen-based wound dressing, and flowable peptide matrix, are designed to enhance MIMEDX's Surgical & Wound product portfolio. The partnership aims to strengthen MIMEDX's offering in the evolving surgical and wound care markets.
2026-02-05 03:59:22
This page provides the latest stock news and market updates for Mimedx Group Inc. (MDXG), a company specializing in regenerative medicine and advanced wound care. It covers announcements regarding new product launches, clinical milestones, financial results, and regulatory developments, offering investors comprehensive insights into the company's performance and strategy.
2026-02-04 16:41:48
MiMedx Group Inc. (MDXG) shares rose approximately 5% after the company announced an exclusive distribution agreement with Summit Products Group for three of its 510(k) cleared products. These products, Hydrelix, NovaForm Wound Matrix, and G4Derm Plus, are designed to complement MiMedx’s existing portfolio for surgical and wound care markets. Retail sentiment on Stocktwits was bullish, with extremely high message volumes regarding the company.
2026-02-04 16:29:07
MIMEDX announced an exclusive distribution agreement with Summit Products Group for three innovative, 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. These products, which include a collagen powder, a bioglass and collagen-based wound dressing, and a flowable peptide matrix, are designed to enhance MIMEDX’s surgical and wound product portfolio. The agreement aims to strengthen MIMEDX’s position in the evolving surgical and wound markets.
